atelfo.github.io/2022/06/02/where-are-the-other-luxturnas.html
Preview meta tags from the atelfo.github.io website.
Linked Hostnames
19- 6 links tomedlineplus.gov
- 3 links toatelfo.github.io
- 2 links toclinicaltrials.gov
- 2 links toendpts.com
- 2 links totwitter.com
- 2 links towww.nature.com
- 1 link toen.wikipedia.org
- 1 link tonewdigs.mit.edu
Search Engine Appearance
Where are the other Luxturna’s? Challenges with gene therapy for inherited retinal diseases
Luxturna, approved in December 2017 in the US1 and November 2018 in the EU2, is a landmark in the history of gene therapy and a transformative3 treatment for patients with inherited retinal disease (IRD) caused by biallelic RPE65 mutations. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss ↩ https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna ↩ https://www.biopharmadive.com/news/luxturna-gene-therapy-eye-leber-lca/609832/ ↩
Bing
Where are the other Luxturna’s? Challenges with gene therapy for inherited retinal diseases
Luxturna, approved in December 2017 in the US1 and November 2018 in the EU2, is a landmark in the history of gene therapy and a transformative3 treatment for patients with inherited retinal disease (IRD) caused by biallelic RPE65 mutations. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss ↩ https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna ↩ https://www.biopharmadive.com/news/luxturna-gene-therapy-eye-leber-lca/609832/ ↩
DuckDuckGo
Where are the other Luxturna’s? Challenges with gene therapy for inherited retinal diseases
Luxturna, approved in December 2017 in the US1 and November 2018 in the EU2, is a landmark in the history of gene therapy and a transformative3 treatment for patients with inherited retinal disease (IRD) caused by biallelic RPE65 mutations. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss ↩ https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna ↩ https://www.biopharmadive.com/news/luxturna-gene-therapy-eye-leber-lca/609832/ ↩
General Meta Tags
10- titleWhere are the other Luxturna’s? Challenges with gene therapy for inherited retinal diseases | Alex’s blog
- charsetutf-8
- X-UA-CompatibleIE=edge
- viewportwidth=device-width, initial-scale=1
- generatorJekyll v3.10.0
Open Graph Meta Tags
6- og:titleWhere are the other Luxturna’s? Challenges with gene therapy for inherited retinal diseases
og:localeen_US- og:descriptionLuxturna, approved in December 2017 in the US1 and November 2018 in the EU2, is a landmark in the history of gene therapy and a transformative3 treatment for patients with inherited retinal disease (IRD) caused by biallelic RPE65 mutations. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss ↩ https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna ↩ https://www.biopharmadive.com/news/luxturna-gene-therapy-eye-leber-lca/609832/ ↩
- og:urlhttps://atelfo.github.io/2022/06/02/where-are-the-other-luxturnas.html
- og:site_nameAlex’s blog
Twitter Meta Tags
1- twitter:cardsummary
Link Tags
5- alternatehttps://atelfo.github.io/feed.xml
- canonicalhttps://atelfo.github.io/2022/06/02/where-are-the-other-luxturnas.html
- stylesheet/assets/css/style.css
- stylesheethttps://fonts.googleapis.com/css?family=merriweather
- stylesheet/css/override.css
Emails
1Links
30- https://atelfo.github.io
- https://atelfo.github.io/2022/06/02/where-are-the-other-luxturnas.html
- https://atelfo.github.io/feed.xml
- https://clinicaltrials.gov/ct2/show/NCT02599922
- https://clinicaltrials.gov/ct2/show/NCT04671433?term=meiragtx&phase=2&draw=2&rank=2